3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
MaxCyte reported preliminary, unaudited third quarter 2026 core business revenue of approximately $8.1 million, up 26% from the third quarter of 2025, and raised its full-year 2026 revenue guidance to approximately $34 million from $30 million to $32 million. The company said the results are subject to change and not audited, but described third quarter and second half revenue as ahead of its expectations, driven by accelerated instrument purchasing from a large customer and a milestone from an SPL partner.
Preliminary Q3 2026 core business revenue of approximately $8.1 million, up 26% year over year; SPL Program-related revenue of more than $1.0 million, including $1.0 million in milestone revenue.
Full-year 2026 revenue guidance raised to approximately $34 million from $30 million to $32 million.
Core business revenue guidance raised to approximately $28 million from $25 million to $27 million; SPL Program-related guidance raised to approximately $6 million from approximately $5 million.
Results are unaudited and subject to change; full third quarter results and royalty revenue will be reported on November 10, 2026.
At its October 14, 2026 Investor Day, Accenture furnished a presentation reporting fiscal 2026 results against its original guidance and setting multi-year ambitions for fiscal 2027 through 2029. Adjusted EPS of $13.97 and free cash flow of $11.6 billion came in above the original guidance ranges, and the company returned $11.5 billion to shareholders. The new ambitions call for mid-single-digit revenue growth in fiscal 2027 and 2028, mid to high-single-digit growth in 2029, and 10 to 30 basis points of margin expansion each year.
FY26 adjusted EPS was $13.97, above the original guidance range of $13.52 to $13.90.
FY26 free cash flow was $11.6 billion, versus original guidance of $9.8 billion to $10.5 billion.
FY26 revenue grew 5% in local currency, at the top of the original 2% to 5% guidance range.
Targets for FY27 to FY29 include 10 to 30 basis points of operating margin expansion each year and free cash flow of at least 1.1 times net income.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.